Cytomyx Share Discussion Threads

[ajrice] 17/12/2004 10:46

......agreed; lowering the share price on previous occasions has had absolutely no selling effect. In any case, because of the wide spread this is not an easy share to trade so I suspect most CYX holders are at least medium to long termers, as indeed am I.
aj.

[boadicea] 16/12/2004 20:00

Looks to me a bit like an mm shake that went wrong, producing mainly buyers.

[ajrice] 16/12/2004 17:24

So at close the fall in share price was halved. Wouldn't be surprised if tomorrow the 1p loss is reversed. I continue to hold.
aj.

[gaybriefs] 16/12/2004 15:42

Hope youre right ok,yah had enough of bombing stocks over the last 6 weeks.All my stocks have bombed and not one of them has reported anything negative only positive ..at the minute I give up!

[ok,yah] 16/12/2004 15:30

i'm in these look like a bargain - lots of room for disappointment in results at these prices we've had 9 months of results so we have a pretty good idea of whats going to come up anyway

[gaybriefs] 16/12/2004 14:37

This is starting to look a bit dodgy especially if a large T Trade sell turns up after the bell.We will have to see but past experiences of mine send the alarm bells ringing when a stock starts pluming all time lows when the results are just round the corner!!

[bernieboy] 16/12/2004 13:06

Well over sold ! Patience required me thinks....

[rbonnier] 16/12/2004 12:16

All of 24600 shares then by the looks of it ill have another 9000 then at 13.75p thanks.!

[rbonnier] 16/12/2004 11:21

Lets see what happens around 12 oclock the trades are delayed by 2 hours Ive held this stock for a while and I dont think it should be trading at 13p unless like you say ajrice the city knows something we dont.

[ajrice] 16/12/2004 11:07

There has been virtually no trades today to cause a 13% fall. Either there is a big sell in the wings or the City knows something we don't. All recent news has been very positive so I don't understand the fall. Another possibility is that the mm's are trying to panick holders into selling, in which case there could be a large buy order to be filled. My guess is tomorrow, that if sufficient sell trades have gone through, the share price may well reverse and go north; it's happened before with this share.
aj.

[rbonnier] 16/12/2004 10:56

Anyone heard anything on this seems to be in terminal decline looks like a write off to me.I think you have to divide the current share price by 25 to get the share price before the consolidation.These also went over 2p at one time so to say they are now the equivalent of sub 1/2p something must be seriously wrong or am I wrong?

[venomousviper] 07/12/2004 12:48

Got my eye on these the share price is well well down and is about to dabble with 1/2p again pre consolidation price.There is also a seller in the market which should be noted as its just before the preliminary announcement.

[ajrice] 30/11/2004 17:12

Re RNS re EGM concerning Clinomics; appears to me to be good news that CYX are proposing to accelerate the conclusion of the purchase. This will give CYX absolute and immediate control of the Clinomics business. The market also seems to like the news.
aj.

[gaybriefs] 30/11/2004 14:53

Theres that 100k buyer again thats 2 within a week I wonder if they know something.Results are in 2/3 weeks time watch for any further buying evidence if more large buys go through Im buying more.

[ajrice] 26/11/2004 10:37

>GayBriefs - Agreed.
aj.

[gaybriefs] 26/11/2004 10:34

These shares are too cheap I have just bought 10k at 16.25p which equates to 0.65p before the consolidation.Should be some news flow over the next few months with prelims in December reckon these are oversold and will bounce.

[raldo] 25/11/2004 18:02

A tick up today and decent volume - is something a'cooking??

[ajrice] 08/11/2004 11:20

>brownie69: Thanks for that; much appreciated.
aj.

[brownie69] 08/11/2004 01:12

House brokers view:


Positive impact of reinstatement of contract

Cytomyx has anounced that it will begin distributing Molecular Probes' products through Cambridge BioScience. Cambridge BioScience previously distributed these products until May 2004 when the distribution agreement was terminated, following the acquisition of Molecular Probes by Invitrogen. The distribution agreement as been re-established for an intitial two year period. However, the agreement is now non-exclusive and Cambridge BioScience will be selling the Molecular Probes range alongside the Invitrogen sales force. We estimate that the Molecular Probes range previously accounted for approximately £1.5m in turnover for Cambridge BioScience which we removed from forecasts following the termination of the distribution agreement. Given that Cambridge BioScience will now be competing with Invitrogen for sales, we believe any positive impact on Cytmoyx's turnover and earnings will be limited and Cambridge BioScience is only likely to recover a proportion of the original £1.5m in sales.
This distribution agreement is likely to have a positive effect on near term revenues and earnings for Cytomyx. However, we believe the key driver of growth for the company will be its Clinomics subsidiary. The validation of Clinomics' technology by te Moffitt Cancer Center collaboration and the potential expansion of the Clinomics range provide long-term upside to the stock. In addition, the prospect of further deals, similar to that signed with AstraZeneca for the licensing of its Oncology Cell Signalling Database, provide the potential for near-term news flow driven upside.



T&G Brokership

Principal Activities
Cytomyx provides research products to pharmaceutical and biotechnology companies. It has expanded its sales and marketing activities through the acquisition of Cambridge BioScience, and sells its services and products through this distribution network, along with the reagents Cambridge BioScience distributes. Cytomyx has also acquired the trade and assets of Cytocell which further expands its product range. In January 2004, Cytoymx acquired Clinomics Bioscience which will be a key driver for the company.

For the purposes of the Financial Services Authority's requirements in relation to Conflicts of Interest management, the content of this communication is categorised as non-objective. Please refer to www.teathers.com for a summary of our Conflicts of Interest Policy and Procedures.

[bladesfan] 21/10/2004 12:30

these are about to take a plunge look at the charts and the french curves

SELL

[brownie69] 21/10/2004 10:24

Got matched at 17.5p! MM's and their games.
Will probabily go through as a late trade.

[brownie69] 21/10/2004 10:17

Trying to buy 50k at 18 if anyone wants to watch the MM games.
Looks like i should get 10 according to L2 but will be interesting to see if anyone hits the rest.

[brownie69] 21/10/2004 10:08

Hmmn, makes enjoyable reading although its a shame they did not sauy anything about likely impact of this contract.
Liked the last bit;
"early indications suggest that a number of major accounts are planning to
purchase products directly from us once more".

[raldo] 21/10/2004 07:47

Cytomyx Holdings PLC
21 October 2004


For immediate release 21 October 2004


CYTOMYX HOLDINGS PLC
('Cytomyx' or the 'Company')

Molecular Probes distribution contract reinstated


Cytomyx Holdings plc (AIM: CYX), a leading provider of drug discovery products
and services, is pleased to announce that Cambridge BioScience, its UK based
research products business, has entered into a non-exclusive distribution
agreement with Invitrogen Corporation to distribute Molecular Probes' products.

Molecular Probes was acquired by Invitrogen in August 2003, resulting in the
termination of Cambridge BioScience's previous distribution agreement with
Molecular Probes at the end of May 2004.

This distribution relationship has now been re-established for an initial term
of two years. Whilst the Company believes it is too early to forecast the impact
on future sales and profitability, the agreement is seen as being a positive
development, which highlights the effectiveness of Cambridge BioScience's
distribution capabilities within the UK life science market.

Mike Kerins, Cytomyx' Chief Executive, said: 'We are delighted to be working
with Molecular Probes once again. Sales of its products had historically
contributed significant revenues to the Company and we look forward to
re-establishing a proportion of this business in the future. Since we shall be
selling the Molecular Probes range alongside the Invitrogen sales force it is
difficult to predict the level of sales that we will be able to achieve, but
early indications suggest that a number of major accounts are planning to
purchase products directly from us once more.'


ENDS



For further information, please contact:

Cytomyx Holdings plc
Mike Kerins, Chief Executive 01223 508191

Buchanan Communications 020 7466 5000
Mark Court/Mary-Jane Johnson

The Wall Street Group, Inc. [phone]
Ron Stabiner



Notes for editors

About Cytomyx Holdings plc

Cytomyx Holdings plc (
www.cytomyx-holdings.com
) is a rapidly growing life
science company based in Cambridge, UK. Its four operating subsidiaries -
Cytomyx Ltd, Clinomics Biosciences, Inc., Cambridge BioScience Ltd and Cytocell
Technologies Ltd - develop and market a wide range of products and services to
the pharmaceutical, diagnostics and academic research markets. Cytomyx is listed
on the London Stock Exchange's Alternative Investment Market (AIM).


This information is provided by RNS
The company news service from the London Stock Exchange